New · CUSIP 107924102 · who reports it, how much, and how much it matters to them
16 of the 720 hedge fund managers we track reported shares of BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) on Form 13F for 30 June 2026. Between them they reported USD 204m. The largest position belongs to Cormorant Asset Management, at USD 136m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Cormorant Asset Management1 fund on PPLI.com | USD 136m | 7.0% |
| 2 | ECOR1 Capital3 funds on PPLI.com | USD 22m | 1.0% |
| 3 | Citadel Advisors32 funds on PPLI.com | USD 20m | 0.0% |
| 4 | Armistice Capital1 fund on PPLI.com | USD 13m | 0.2% |
| 5 | Sphera Funds Management1 fund on PPLI.com | USD 3.5m | 0.5% |
| 6 | Adage Capital Management1 fund on PPLI.com | USD 3m | 0.0% |
| 7 | Casdin Capital3 funds on PPLI.com | USD 2.2m | 0.1% |
| 8 | Sio Capital Management4 funds on PPLI.com | USD 995,000 | 0.2% |
| 9 | Millennium Management6 funds on PPLI.com | USD 804,000 | 0.0% |
| 10 | Moore Capital Management7 funds on PPLI.com | USD 762,000 | 0.0% |
| 11 | Brevan Howard Capital Management39 funds on PPLI.com | USD 691,000 | 0.0% |
| 12 | Renaissance Technologies13 funds on PPLI.com | USD 447,000 | 0.0% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 202,000 | 0.0% |
| 14 | Squarepoint Ops7 funds on PPLI.com | USD 150,000 | 0.0% |
| 15 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 87,659 | 0.0% |
| 16 | The Quarry1 fund on PPLI.com | USD 1,501 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Cormorant Asset Management | USD 136m | 7.0% |
| 2 | ECOR1 Capital | USD 22m | 1.0% |
| 3 | Sphera Funds Management | USD 3.5m | 0.5% |
| 4 | Sio Capital Management | USD 995,000 | 0.2% |
| 5 | Armistice Capital | USD 13m | 0.2% |
| 6 | Casdin Capital | USD 2.2m | 0.1% |
| 7 | Moore Capital Management | USD 762,000 | 0.0% |
| 8 | Brevan Howard Capital Management | USD 691,000 | 0.0% |
| 9 | Adage Capital Management | USD 3m | 0.0% |
| 10 | Citadel Advisors | USD 20m | 0.0% |
BridgeBio Oncology Therapeutics, Inc. trades under the symbol BBOT on the Nasdaq. Its CUSIP, the code used on Form 13F, is 107924102.
16 of the 720 hedge fund managers PPLI.com tracks reported BridgeBio Oncology Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Cormorant Asset Management (USD 136m), ECOR1 Capital (USD 22m), Citadel Advisors (USD 20m), Armistice Capital (USD 13m) and Sphera Funds Management (USD 3.5m).
16 managers in our coverage reported it, and between them they run 184 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Cormorant Asset Management, where the position was 7.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with BridgeBio Oncology Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.